	US 12,258,414 B2
	Anti-CD98hc VNARs for crossing the blood brain barrier and type IV VNAR libraries
Krzysztof Bartlomiej Wicher, Cambridge (GB); Jaroslaw Michal Szary, Cambridge (GB); Julia Lynn Rutkowski, Bryn Mawr, PA (US); Fabrizio Comper, Knebworth (GB); and Pawel Stocki, Royston (GB)
Assigned to Ossianix, Inc., Philadelphia, PA (US)
Appl. No. 17/255,378
Filed by Ossianix, Inc., Philadelphia, PA (US)
PCT Filed Jun. 19, 2019, PCT No. PCT/US2019/038021 § 371(c)(1), (2) Date Dec. 22, 2020, PCT Pub. No. WO2019/246288, PCT Pub. Date Dec. 26, 2019.
Claims priority of provisional application 62/688,966, filed on Jun. 22, 2018.
Prior Publication US 2022/0177597 A1, Jun. 9, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C40B 30/04 (2006.01)

CPC C07K 16/2896 (2013.01) [A61P 35/00 (2018.01); C07K 16/2881 (2013.01); C07K 16/2887 (2013.01); C40B 30/04 (2013.01); A61K 2039/505 (2013.01); C07K 2317/22 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/526 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/92 (2013.01)]

16 Claims

1. An isolated CD98hc-specific binding moiety comprising a Type IV VNAR domain capable of specifically binding to human CD98hc and murine CD98hc, wherein said VNAR domain is represented by the formula, from N to C terminus,

FW1-CDR1-FW2-HV2-FW2′-HV4-FW3-CDR3-FW4,

wherein CDR1 comprises the amino acid sequence VHGRALA (SEQ ID NO: 38), HV2 comprises the amino acid sequence TREETISKG (SEQ ID NO: 1), HV4 comprises the amino acid sequence NSGSKS (SEQ ID NO: 3), and CDR3 comprises the amino acid sequence of any one of SEQ ID NOS: 92 or 98-361.